Post-hoc analyses of ARISTOTLE trial (110), RE-LY trial (111), and ENGAGE AF-TIMI 48 trial (112) similarly showed that NT-proBNP was independently associated with the increased risk of IS, and adding NT-proBNP to the CHA2DS2-VASc score could improve C-statistics. This evidence concerns the gene NPPB and atrial fibrillation.